Botanix Pharmaceuticals Limited (BOT) Price & Analysis

Compare

118 Followers

BOT Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$0.13 - AU$0.54

Previous CloseN/A

Volume8.15M

Average Volume (3M)12.38M

Market Cap

AU$294.17M

Enterprise ValueAU$742.80M

Total Cash (Recent Filing)AU$48.44M

Total Debt (Recent Filing)AU$866.35K

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Aug 28, 2025

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding1,961,126,600

10 Day Avg. Volume5,846,611

30 Day Avg. Volume12,383,603

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$1.14

Price Target Upside714.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial HealthWith a strong cash balance of $64.9 million, company management believes it is well-positioned to achieve profitability with its current cash reserve.

Market PotentialThe market for hyperhidrosis treatments is projected to grow from $1.6 billion annually to $2.8 billion by 2030, indicating significant growth potential.

Revenue GrowthSofdra net revenue increased from $0.7 million in 3Q to $4.3 million.

Bears Say

CompetitionSofdra faces competition in the dermatology market, which could impact its ability to capture market share.

Investment RiskThe necessity for strategic investment to further accelerate Sofdra's growth may pose financial risks if returns do not meet expectations.

Botanix Pharmaceuticals Limited News

Botanix Pharmaceuticals Issues Unquoted Equity Securities for Employee Incentives

The latest announcement is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals Limited has announced the...

1d ago

BOT

Botanix Pharmaceuticals to Present at Prestigious Growth Conference

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has shared an update. Botanix Pharmaceuticals announced that its CEO, Dr. Howie...

11d ago

BOT

Botanix Pharmaceuticals Achieves Strong Sales and Prescription Growth

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an update. Botanix Pharmaceuticals Limited reported significant growth in its...

23d ago

BOT

Strong Market Potential and Early Success Drive Buy Rating for Botanix Pharmaceuticals

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Botanix Pharmaceuticals Limited,...

26d ago

Botanix Pharmaceuticals to Host Webinar on Sofdra’s Market Progress and Financial Outlook

The latest announcement is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals announced an upcoming webinar...

1M ago

BOT

Botanix Pharmaceuticals Updates Sofdra Prescription Metrics

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an update. Botanix Pharmaceuticals has corrected its previous announcement regarding...

2M ago

BOT

Promising Market Potential and Strong Sales Metrics Drive Buy Rating for Botanix Pharmaceuticals’ Sofdra

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Botanix Pharmaceuticals Limited today and set a price...

2M ago

Botanix Pharmaceuticals Announces Sofdra™ Launch Update

The latest announcement is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals Limited has announced an...

2M ago

BOT

Botanix Pharmaceuticals Reports Strong Launch for Sofdra

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an update. Botanix Pharmaceuticals has reported strong demand for its...

2M ago

BOT

Botanix Pharmaceuticals to Host Webinar on Sofdra’s Market Success

An announcement from Botanix Pharmaceuticals Limited ( ($AU:BOT) ) is now available. Botanix Pharmaceuticals Limited announced a webinar...

2M ago

BOT

BOT FAQ

What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?

Botanix Pharmaceuticals Limited lowest share price was AU$0.13 and its highest was AU$0.54 in the past 12 months.

What is Botanix Pharmaceuticals Limited’s market cap?

Botanix Pharmaceuticals Limited’s market cap is AU$294.17M.

When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?

Botanix Pharmaceuticals Limited’s upcoming earnings report date is Aug 28, 2025 which is in 5 days.

How were Botanix Pharmaceuticals Limited’s earnings last quarter?

Botanix Pharmaceuticals Limited released its earnings results on Feb 25, 2025. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of AU$0.001 by -AU$0.018.

Is Botanix Pharmaceuticals Limited overvalued?

According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Botanix Pharmaceuticals Limited pay dividends?

Botanix Pharmaceuticals Limited does not currently pay dividends.

What is Botanix Pharmaceuticals Limited’s EPS estimate?

Botanix Pharmaceuticals Limited’s EPS estimate is -0.01.

How many shares outstanding does Botanix Pharmaceuticals Limited have?

Botanix Pharmaceuticals Limited has 1,961,126,600 shares outstanding.

What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?

Botanix Pharmaceuticals Limited reported an EPS of -AU$0.017 in its last earnings report, missing expectations of AU$0.001. Following the earnings report the stock price went down -4%.

Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in AU:BOT

Botanix Pharmaceuticals Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-56.99%

Trailing 12-Months

Asset Growth

108.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited (BOT) is an innovative clinical-stage dermatology company focused on developing treatments for skin diseases using its proprietary drug delivery technology, Permetrex. The company is primarily engaged in the research, development, and commercialization of pharmaceutical products aimed at addressing unmet needs in dermatology, with a focus on conditions such as acne, rosacea, and other skin infections.

Botanix Pharmaceuticals Limited (BOT) Earnings & Revenues

Historic Earnings Reports

BOT Stock 12 Month Forecast

Average Price Target

AU$1.14

▲(714.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","2":"AU$2","3":"AU$3","-1":"-AU$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$1.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Dec<br/>2023","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.31,0.44,0.5700000000000001,0.7,0.8300000000000001,0.96,1.09,1.22,1.35,1.48,1.61,1.7400000000000002,1.87,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.31,0.37384615384615383,0.43769230769230766,0.5015384615384615,0.5653846153846154,0.6292307692307691,0.6930769230769229,0.7569230769230768,0.8207692307692307,0.8846153846153846,0.9484615384615382,1.0123076923076921,1.076153846153846,{"y":1.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.31,0.3069230769230769,0.3038461538461538,0.3007692307692308,0.2976923076923077,0.2946153846153846,0.2915384615384615,0.2884615384615385,0.2853846153846154,0.2823076923076923,0.2792307692307692,0.2761538461538462,0.2730769230769231,{"y":0.27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.1,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.09,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.08,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.18,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.14,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.16,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.16,"date":1701388800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >